Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;65(5):834-840.
doi: 10.1111/trf.18195. Epub 2025 Apr 13.

HIV incidence in US first-time blood donors during 12 and 3 month deferral policy periods between 2015 and 2023 before implementation of individual donor assessment

Eduard Grebe  1 , Clara Di Germanio  1 , Edward P Notari 4th  2 , Mars Stone  1   3 , Jahnavi Reddy Bhaskar  1 , Venkata Dayana  1 , Marion C Lanteri  3   4 , Jed Gorlin  5 , Rita Reik  6 , Susan L Stramer  7 , Michael P Busch  1   3 , Benyam Hailu  8 , Artur A Belov  9 , Hong Yang  9 , Barbee Whitaker  9 , Brian Custer  1   3 ; US Transfusion‐Transmissible Infections Monitoring System (TTIMS)
Collaborators, Affiliations

HIV incidence in US first-time blood donors during 12 and 3 month deferral policy periods between 2015 and 2023 before implementation of individual donor assessment

Eduard Grebe et al. Transfusion. 2025 May.

Abstract

Background: Following FDA guidance, US blood collectors changed donor deferral for men who have sex with men (MSM) from indefinite to a 12 month deferral in 2016 (12 m), and for MSM and several other exposure risks to 3 month deferrals in 2020 (3 m). We evaluated first-time donor (FTD) HIV incidence and demographics during these periods.

Study design and methods: We estimated cross-sectional HIV incidence and incidence rate differences in FTD based on routine donation nucleic acid testing (NAT) and serology with additional limiting antigen (LAg)-Avidity immunoassay and viral load testing. We estimated incidence in the two policy periods (12 and 3 m), incidence trends in two-year intervals between 2015 and 2023, and used multivariable Poisson regression to assess demographic correlates of incident infection.

Results: HIV incidence in FTD during the 12 m deferral period was 2.82 infections/105 person-years (PY) [95% CI: 2.12, 3.67] and during the 3 m deferral period, it was 1.88/105 PY (95% CI: 1.18, 2.67), a statistically significant decline (p < .05). Over the period 2015-2023, incidence was stable. Male sex, younger age, Black or African American race, Hispanic ethnicity, and residence in the South were associated with incident infection in regression analysis, but the time-based deferral policy periods were not.

Discussion: HIV incidence in FTD did not increase between 2015 and 2023. An overall decline in HIV incidence in the 3 m deferral period compared with the 12 m deferral period was evident. These results provide no indication of an increased residual risk of transfusion-transmitted HIV from FTD in the United States with the reduced deferral periods.

Keywords: HIV; transfusion‐transmitted disease.

PubMed Disclaimer

References

    1. Food and Drug Administration. Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products: Guidance for Industry. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2015.
    1. Food and Drug Administration. Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products: Guidance for Industry. In: Research CfBEa, editor. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2020.
    1. Food and Drug Administration. Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Redcuce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2023.
    1. Custer B, Stramer SL, Glynn S, Williams AE, Anderson SA. Transfusion-transmissible infection monitoring system: a tool to monitor changes in blood safety. Transfusion. 2016;56(6 Pt 2):1499–502. - PMC - PubMed
    1. Steele WR, Dodd RY, Notari EP, Haynes J, Anderson SA, Williams AE, et al. HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men. Transfusion. 2021;61(3):839–50. - PubMed

LinkOut - more resources